Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Healthy volunteers, ages 18 to 49 years old * BMI 18 to 32 kg/m2 * Women must not be pregnant or breastfeeding Exclusion Criteria: * A personal history of clinically relevant cardiac disease, symptomatic or asymptomatic arrhythmias, presyncope or syncopal episodes, or additional risk factors for torsades de pointes (eg, heart failure) * History of hypokalemia, personal history or family history of prolonged QT interval, or family history of sudden cardiac death at a young age * Any of the following on 12-lead electrocardiogram (ECG) prior to study drug administration: PR ≥210 msec, QRS ≥120 msec, QT ≥500 msec, QTcF ≥450 msec, HR \<45 bpm * Second or third degree heart block prior to study drug * Positive urine screen for drugs of abuse * Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or Human Immunodeficiency Virus (HIV)-1, -2 antibody * Any of the following lab results outside of the ranges specified below prior to dosing: Alanine aminotransferase (ALT) \>upper limit of normal (ULN), aspartate aminotransferase (AST) \>ULN, Total bilirubin \>ULN, Direct bilirubin \>ULN, Creatinine \>ULN, Serum potassium \<lower limit of normal (LLN), Serum magnesium \<LLN * History of allergy to Moxifloxacin, Efavirenz or related compounds